上海德建聪和生物医药科技

Dejian Conghe is a Shanghai-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology and other serious diseases. Founded by Dr. Dejian Li, a leading expert in medicinal chemistry and a key figure in the development of the first clinical SHP2 inhibitors, the company utilizes a proprietary structure-based drug design (SBDD) platform integrated with artificial intelligence. Their research prioritizes challenging targets such as protein-protein interactions (PPIs) and signaling hubs that have historically been considered difficult to drug. The company's pipeline includes several promising programs targeting the RAS/MAPK signaling pathway, aiming to provide next-generation treatments for patients with solid tumors. By combining deep biological insights with advanced computational tools, Dejian Conghe seeks to accelerate the drug discovery process and improve clinical success rates. The firm is backed by prominent venture capital investors and is headquartered in the Zhangjiang Hi-Tech Park.